Intercept Pharmaceuticals ( ) - 株価, ニュースと分析Nasdaq:ICPT

ICPT 株式概要

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. 詳細

ICPT ファンダメンタル分析
スノーフレーク・スコア
評価	5/6
将来の成長	4/6
過去の実績	0/6
財務の健全性	5/6
配当金	0/6

報酬

当社が推定した公正価値より53.1%で取引されている

収益は年間42.37%増加すると予測されています

過去5年間の収益は年間22.4%増加しました。

同業他社や業界と比較して、良好な取引価格

リスク分析

過去3か月間の株価の変動は非常に激しい

Intercept Pharmaceuticals, Inc. 競合他社

Avid Bioservices

NasdaqCM:CDMO

US$783.5m

Immatics

NasdaqCM:IMTX

US$904.7m

Ironwood Pharmaceuticals

NasdaqGS:IRWD

US$534.5m

Prothena

NasdaqGS:PRTA

US$777.0m

価格と性能

の歴代最高値、変動、値下がりまとめIntercept Pharmaceuticals
過去の株価
現在の株価	US$19.00
52週高値	US$21.86
52週安値	US$8.82
ベータ	0.88
11ヶ月の変化	1.99%
3ヶ月変化	81.30%
1年変化	19.12%
33年間の変化	-50.68%
5年間の変化	-81.17%
IPOからの変化	-2.06%

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

株主還元

	ICPT	US Biotechs	US 市場
7D	0.1%	2.4%	2.2%
1Y	19.1%	16.2%	31.7%

業界別リターン: ICPT過去 1 年間で16.2 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: ICPT過去 1 年間で31.7 % の収益を上げたUS市場を上回りました。

価格変動

Is ICPT's price volatile compared to industry and market?
ICPT volatility
ICPT Average Weekly Movement	22.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

安定した株価: ICPTの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ICPTの週次ボラティリティは、過去 1 年間で15%から23%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc. 基礎のまとめ

Intercept Pharmaceuticals の収益と売上を時価総額と比較するとどうか。
ICPT 基礎統計学
時価総額	US$794.69m
収益（TTM）	-US$57.47m
売上高(TTM)	US$317.68m

2.5x

P/Sレシオ

-13.8x

PER（株価収益率

ICPT は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ICPT 損益計算書（TTM）
収益	US$317.68m
売上原価	US$632.00k
売上総利益	US$317.05m
その他の費用	US$374.52m
収益	-US$57.47m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-1.37
グロス・マージン	99.80%
純利益率	-18.09%
有利子負債／自己資本比率	311.6%

ICPT の長期的なパフォーマンスは？

過去の実績と比較を見る

ICPT 株式概要

報酬

リスク分析

Intercept Pharmaceuticals, Inc. 競合他社

NasdaqCM:CDMO

US$783.5m

NasdaqCM:IMTX

US$904.7m

NasdaqGS:IRWD

US$534.5m

NasdaqGS:PRTA

US$777.0m

価格と性能

最新ニュース

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings: EPS exceeds analyst expectations

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Price target decreased by 24% to US$15.08

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Price target decreased by 14% to US$21.00

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.9% to US$24.00

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.2% to US$20.85

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Consensus forecasts updated

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Consensus forecasts updated

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Price target decreased to US$24.00

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Intercept cuts debt further with deal to exchange convertible notes

Intercept reduces debt with repurchases of $327.9M convertible notes

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Intercept Pharma Q2 2022 Earnings Preview

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Intercept: Increase Of Ocaliva Sales And A Few Catalysts